ROI AND INNOVATION IN DRUG DEVELOPMENT: WHAT ARE BIG AND LITTLE BIOPHARMAS DOING TO CHANGE THE EQUATION?

To hear the experts tell it, the ROI on drug development at Big Pharma has been falling for the past decade, and may well head into negative terrain soon. The implications for biotech are huge. Will smaller companies become the sole engine of early-stage innovation? Can Big Pharma save itself from poor productivity records, as evident in Europe as well as the US? What’s happening here and what new technologies — like AI — will play a key role in determining the future? Let's also not forget the role the current pricing debate in the US will play in determining the winners and losers of the future.